国のhonorariaのデータベースと公的保険データベースから解析されてます。 0428名無しさん@お腹いっぱい。2018/06/30(土) 10:14:17.46>>427 日本でも情報公開が進んでるから、解析可能なんじゃないかな? もうどこかの経済学者と統計学者が解析進めてるかも。また、中医協の薬価制度の部会への有力なエビデンスになりますね。 0429名無しさん@お腹いっぱい。2018/06/30(土) 21:46:14.57 欧米の統計データみると、日本でも、間違いなく統計学的に結果でると思います。 0430名無しさん@お腹いっぱい。2018/07/01(日) 06:55:33.15 Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians’ attitudes and prescribing habits: a systematic review Freek Fickweiler
この報告も統計学的に結果出てます。 0431名無しさん@お腹いっぱい。2018/07/01(日) 07:08:01.46>>430 Gifts、 Drug samples、 Pharmaceutical representative speakers、 Honoraria and research funding、 Conference travel、 Industry-paid lunches、 CME sponsorship
Doctors and teaching hospitals received $8.4 billion from drug and device companies in 2017, according to the latest Centers for Medicare and Medicaid Services Open Payments data.
Open Payments published 11.54 million payment records. Payments included nearly $4.7 billion in research-related payments, $2.82 billion in non-research-related payments, such as meals, fees and travel to speaking events and more than $927 million in ownership or investment interests held by physicians or immediate family members. About 628,000 doctors received $79.1 million in research-related payments.
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program ― $560 million.
Doctors and teaching hospitals received $8.4 billion from drug and device companies in 2017, according to the latest Centers for Medicare and Medicaid Services Open Payments data.
Open Payments published 11.54 million payment records. Payments included nearly $4.7 billion in research-related payments, $2.82 billion in non-research-related payments, such as meals, fees and travel to speaking events and more than $927 million in ownership or investment interests held by physicians or immediate family members. About 628,000 doctors received $79.1 million in research-related payments.
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program ― $560 million.
Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review.
OBJECTIVES: The objective of this review is to explore interactions between physicians and the pharmaceutical industry including sales representatives and their impact on physicians' attitude and prescribing habits.
CONCLUSION: Physician-pharmaceutical industry and its sales representative's interactions and acceptance of gifts from the company's PSRs have been found to affect physicians' prescribing behaviour and are likely to contribute to irrational prescribing of the company's drug. Therefore, intervention in the form of policy implementation and education about the implications of these interactions is needed. 0448名無しさん@お腹いっぱい。2018/07/08(日) 10:08:48.94 これもリアルワールドエビデンスの結果です。
フランス保健省は、上記4種類の治療薬について、さまざまな副作用が懸念される一方 で、期待するような効果を示すエビデンス(医学上の根拠)が十分に得られなかった として、「医療保険でカバーするのは適切ではない」という判断を下し、今年の8月 から医療保険を適用しないことを決めました。 0449名無しさん@お腹いっぱい。2018/07/10(火) 21:13:17.72 Pfizer & others should be ashamed that they have raised drug prices for no reason.
President Trump tweeted.
They are merely taking advantage of the poor & others unable to defend themselves, while at the same time giving bargain basement prices to other countries in Europe & elsewhere.
We will respond!” 0450名無しさん@お腹いっぱい。2018/07/11(水) 07:12:20.56 The list price remains unchanged for the majority of our medicines.
Our portfolio includes more than 400 medicines and vaccines;
we are modifying prices for approximately 10 percent of these, including some instances where we're decreasing the price,
a spokesperson for Pfizer emailed.
List prices do not reflect what most patients or insurance companies pay.
In the first quarter of 2018 the net selling price increase was 0 percent due to the growing amount of rebates paid back to stakeholders in the biopharmaceutical supply chain. 0451名無しさん@お腹いっぱい。2018/07/11(水) 20:31:19.63 値上げ撤回。 トランプ大統領のツイート。
Just talked with Pfizer CEO and @SecAzar on our drug pricing blueprint. Pfizer is rolling back price hikes, so American patients don’t pay more. We applaud Pfizer for this decision and hope other companies do the same. Great news for the American people! 0452名無しさん@お腹いっぱい。2018/07/13(金) 07:04:57.65 製薬協の上部団体である国際製薬団体連合会(IFPMA)の理事会で、コードが改訂され、ギフトが全面的に禁止されました。
Of 107 physician advisers who voted on the committees 40 over a nearly 4-year period received more than $10,000 in post hoc earnings or research support from the makers of drugs that the panels voted to approve, or from competing firms; 26 of those gained more than $100,000; and seven more than $1 million.
Of the more than $26 million in personal payments or research support from industry to the 17 top-earning advisers―who received more than $300,000 each―94% came from the makers of drugs those advisers previously reviewed or from competitors.
Most of those top earners―and many others―received other funds from those same companies, concurrent with or in the year before their advisory service. 0455名無しさん@お腹いっぱい。2018/07/13(金) 23:35:43.96 利益供与。どっちも犯罪だろ。医者って19世紀から進歩しないな。 0456名無しさん@お腹いっぱい。2018/07/14(土) 13:47:07.17 虻川です。
現行の薬価の数パーセントの医療機関向けインセンティブは拡大。 現行の薬価ASPとinternational pricing data IPIを初年度は、20対80、次年度40対60、5年後0対100
以下の国の薬価を参考に薬価引き下げを毎年5年間実施。 Austria, Belgium, Canada, Czech Republic, Finland, France, Germany, Greece, Ireland, Italy, Japan, Portugal, Slovakia, Spain, Sweden, and the United Kingdom (UK).
参考 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services 42 CFR CHAPTER IV [CMS-5528-ANPRM] RIN 0938-AT91 Medicare Program; International Pricing Index Model for Medicare Part B Drugs 0501名無しさん@お腹いっぱい。2018/10/30(火) 21:59:44.73 トランプ大統領 公的保険メディケアの薬価削減策発動。
60日間のパブリックオピニオン。 来年春に公布、2020年春に施行。 5年計画の薬価削減策を実施。
現行の薬価の数パーセントの医療機関向けインセンティブは拡大。 現行の薬価ASPとinternational pricing data IPIを初年度は、80対20、次年度60対40、5年後0対100
上位100製品を想定。
以下の国の薬価を参考に薬価引き下げを毎年5年間実施。 Austria, Belgium, Canada, Czech Republic, Finland, France, Germany, Greece, Ireland, Italy, Japan, Portugal, Slovakia, Spain, Sweden, and the United Kingdom (UK).